2023-05-19 09:20:40 ET
- Stereotaxis ( NYSE: STXS ) is collaborating with Abbott Laboratories ( NYSE: ABT ) to combine mapping and robotic technologies to improve treatment of abnormal heart rhythms.
- The partnership will integrate Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems.
- The companies said the the combination of Abbott's cardiac mapping system with Stereotaxis' robotic technology brings together detailed real-time diagnostic information with precision and stability of robotics during therapy delivery.
- The integrated technologies are cleared for use in Europe with additional regulatory clearances expected in the coming months, the companies noted .
- STXS +8.88% to $1.84 premarket May 19
-
More on Abbott
- Abbott Remains A Top Pick For Dividend Investors
For further details see:
Stereotaxis stock rises after pact with Abbott to improve abnormal heart beat treatment